Yuexiu Financial Holdings was listed in the main board of Shenzhen Stock Exchange in 2
Guangzhou Yuexiu Financial Holdings Group, founded in 1992, was listed in the main board of Shenzhen Stock Exchange in 2000, is the first local financial holdings listed platform in China, has controls over several financial institutions, and is the second-largest shareholder of CITIC Securities. The business areas include securities, financial leasing, industrial fund, guarantee, microcredit and merchandise. Its major shareholders are Guangzhou Yuexiu Holding, Guangzhou State-owned Asset Development Holding, and Guangzhou Hengyun Enterprises Holdings. Its direct and indirect competitors include CNPC Capital, Avic Capital and Minmetals Capital.
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
“I entered the venture capital industry in 2008. I experienced the financial crisis in 2009 and the boom of the classical venture capital model from 2011 to 2015. Having experienced many ups and downs, I believe that venture capital will tide over the tough period and usher in new opportunities.”
May 12, 2022 05:41 PM
Electrophysiology AccuPulse Raises Nearly CNY 100 Million in Series A Funding
Founded in November 2020, Suzhou AccuPulse is committed to becoming an international leading platform-based innovative cardiac electrophysiology company. The company has established a research and development team led by well-known electrophysiological experts in the US with R&D centers in Suzhou and in the United States.
May 20, 2022 05:17 PM
IDG Backed Weimu Medical Raises CNY Tens of Millions Series Pre-A Funding Round
Founded in 2020, Shanghai Weimu Medical has built a high-end interventional medical device platform that is based on innovative materials in the fields of tumor intervention and pan-vascular intervention. The company has developed a number of products such as microspheres hydrogels and tissue adhesives.
May 19, 2022 07:13 PM
Cell Therapy Developer Senlang Bio Raises CNY 200 Million in New Funding Round
Founded in 2016, Hebei Senlang Bio is a clinical-stage biotechnology company dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers.
May 18, 2022 01:00 PM